Linagliptin/Metformin Sandoz

Linagliptin and Metformin Hydrochloride, the active ingredients in Linagliptin/Metformin Sandoz, are a DPP‑4 inhibitor and a biguanide presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients.

GNH USA supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution. The company adheres to EU GMP standards and offers flexible order volumes to meet the needs of diverse healthcare providers.

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

Type 2 diabetes mellitus: improves glycemic control as part of a comprehensive treatment plan that includes diet and exercise. Patients inadequately controlled on metformin alone: provides additional glucose‑lowering effect when combined with metformin. Combination therapy with other antidiabetic agents: can be used alongside sulfonylureas, insulin, or SGLT2 inhibitors to achieve target HbA1c.

Like all antidiabetic agents, Linagliptin/Metformin may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or upset stomach - Diarrhea or loose stools - Headache - Dizziness - Mild hypoglycemia when used with sulfonylureas or insulin - Metallic taste

Serious or Rare Side Effects: - Lactic acidosis (especially in renal impairment) - Acute pancreatitis - Severe hypersensitivity reactions (e.g., angioedema, Stevens‑Johnson syndrome) - Hepatic failure - Significant renal function decline - Persistent vomiting or abdominal pain

Patients should be evaluated for renal and hepatic function before initiating therapy, and monitored regularly during treatment.

Renal function monitoring: assess eGFR before starting and periodically thereafter. Hepatic function monitoring: check liver enzymes at baseline and as clinically indicated. Risk of lactic acidosis: avoid in patients with severe renal impairment or conditions predisposing to hypoxia. Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited. Drug‑interaction vigilance: review concomitant medications that may affect metformin clearance or increase hypoglycemia risk. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Linagliptin/Metformin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk. - Iodinated contrast agents: discontinue metformin before and after imaging to prevent accumulation. - Carbamazepine: induces metabolism, reducing linagliptin exposure. - Cimetidine: may increase metformin plasma concentrations. - Rifampicin: decreases linagliptin levels, reducing glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycemia; adjust dose as needed. - Diuretics (especially thiazides): may impair renal function, raising metformin levels. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - NSAIDs: can affect renal clearance of metformin. - Beta‑blockers: may mask hypoglycemia symptoms.